Cargando…

Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study

BACKGROUND: There is an increasing body of literature reporting treatment failure of the currently recommended radical treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging tolerance to its radical treatment regime could have major...

Descripción completa

Detalles Bibliográficos
Autores principales: Van den Eede, Peter, Soto-Calle, Veronica E., Delgado, Christopher, Gamboa, Dionicia, Grande, Tanilu, Rodriguez, Hugo, Llanos-Cuentas, Alejandro, Anné, Jozef, D'Alessandro, Umberto, Erhart, Annette
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030575/
https://www.ncbi.nlm.nih.gov/pubmed/21297986
http://dx.doi.org/10.1371/journal.pone.0016257
_version_ 1782197278487871488
author Van den Eede, Peter
Soto-Calle, Veronica E.
Delgado, Christopher
Gamboa, Dionicia
Grande, Tanilu
Rodriguez, Hugo
Llanos-Cuentas, Alejandro
Anné, Jozef
D'Alessandro, Umberto
Erhart, Annette
author_facet Van den Eede, Peter
Soto-Calle, Veronica E.
Delgado, Christopher
Gamboa, Dionicia
Grande, Tanilu
Rodriguez, Hugo
Llanos-Cuentas, Alejandro
Anné, Jozef
D'Alessandro, Umberto
Erhart, Annette
author_sort Van den Eede, Peter
collection PubMed
description BACKGROUND: There is an increasing body of literature reporting treatment failure of the currently recommended radical treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging tolerance to its radical treatment regime could have major consequences in countries like Peru, where 80% of malaria cases are due to P. vivax. Here we describe the results of a 1-year longitudinal follow up of 51 confirmed P. vivax patients living around Iquitos, Peruvian Amazon, and treated according to the Peruvian national guidelines. METHODOLOGY: Each month a blood sample for microscopy and later genotyping was systematically collected. Recent exposure to infection was estimated by detecting antibodies against the P. vivax circumsporozoite protein (CSP) and all PCR confirmed P. vivax infections were genotyped with 16 polymorphic microsatellites. RESULTS: During a 1-year period, 84 recurrent infections, 22 positive also by microscopy, were identified, with a median survival time to first recurrent infection of 203 days. Most of them (71%) were asymptomatic; in 13 patients the infection persisted undetected by microscopy for several consecutive months. The genotype of mostly recurrent infections differed from that at day 0 while fewer differences were seen between the recurrent infections. The average expected heterozygosity was 0.56. There was strong linkage disequilibrium (I(A)(s) = 0.29, p<1.10(−4)) that remained also when analyzing only the unique haplotypes, suggesting common inbreeding. CONCLUSION: In Peru, the P. vivax recurrent infections were common and displayed a high turnover of parasite genotypes compared to day 0. Plasmodium vivax patients, even when treated according to the national guidelines, may still represent an important parasite reservoir that can maintain transmission. Any elimination effort should consider such a hidden reservoir.
format Text
id pubmed-3030575
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30305752011-02-04 Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study Van den Eede, Peter Soto-Calle, Veronica E. Delgado, Christopher Gamboa, Dionicia Grande, Tanilu Rodriguez, Hugo Llanos-Cuentas, Alejandro Anné, Jozef D'Alessandro, Umberto Erhart, Annette PLoS One Research Article BACKGROUND: There is an increasing body of literature reporting treatment failure of the currently recommended radical treatment of Plasmodium vivax infections. As P. vivax is the main malaria species outside the African continent, emerging tolerance to its radical treatment regime could have major consequences in countries like Peru, where 80% of malaria cases are due to P. vivax. Here we describe the results of a 1-year longitudinal follow up of 51 confirmed P. vivax patients living around Iquitos, Peruvian Amazon, and treated according to the Peruvian national guidelines. METHODOLOGY: Each month a blood sample for microscopy and later genotyping was systematically collected. Recent exposure to infection was estimated by detecting antibodies against the P. vivax circumsporozoite protein (CSP) and all PCR confirmed P. vivax infections were genotyped with 16 polymorphic microsatellites. RESULTS: During a 1-year period, 84 recurrent infections, 22 positive also by microscopy, were identified, with a median survival time to first recurrent infection of 203 days. Most of them (71%) were asymptomatic; in 13 patients the infection persisted undetected by microscopy for several consecutive months. The genotype of mostly recurrent infections differed from that at day 0 while fewer differences were seen between the recurrent infections. The average expected heterozygosity was 0.56. There was strong linkage disequilibrium (I(A)(s) = 0.29, p<1.10(−4)) that remained also when analyzing only the unique haplotypes, suggesting common inbreeding. CONCLUSION: In Peru, the P. vivax recurrent infections were common and displayed a high turnover of parasite genotypes compared to day 0. Plasmodium vivax patients, even when treated according to the national guidelines, may still represent an important parasite reservoir that can maintain transmission. Any elimination effort should consider such a hidden reservoir. Public Library of Science 2011-01-28 /pmc/articles/PMC3030575/ /pubmed/21297986 http://dx.doi.org/10.1371/journal.pone.0016257 Text en Van den Eede et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Van den Eede, Peter
Soto-Calle, Veronica E.
Delgado, Christopher
Gamboa, Dionicia
Grande, Tanilu
Rodriguez, Hugo
Llanos-Cuentas, Alejandro
Anné, Jozef
D'Alessandro, Umberto
Erhart, Annette
Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
title Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
title_full Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
title_fullStr Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
title_full_unstemmed Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
title_short Plasmodium vivax Sub-Patent Infections after Radical Treatment Are Common in Peruvian Patients: Results of a 1-Year Prospective Cohort Study
title_sort plasmodium vivax sub-patent infections after radical treatment are common in peruvian patients: results of a 1-year prospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030575/
https://www.ncbi.nlm.nih.gov/pubmed/21297986
http://dx.doi.org/10.1371/journal.pone.0016257
work_keys_str_mv AT vandeneedepeter plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT sotocalleveronicae plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT delgadochristopher plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT gamboadionicia plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT grandetanilu plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT rodriguezhugo plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT llanoscuentasalejandro plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT annejozef plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT dalessandroumberto plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy
AT erhartannette plasmodiumvivaxsubpatentinfectionsafterradicaltreatmentarecommoninperuvianpatientsresultsofa1yearprospectivecohortstudy